Last €68.37 EUR
Change Today +2.61 / 3.97%
Volume 11.1K
MDT On Other Exchanges
Symbol
Exchange
New York
Mexico
Frankfurt
As of 1:20 PM 01/23/15 All times are local (Market data is delayed by at least 15 minutes).

medtronic inc (MDT) Snapshot

Open
€66.04
Previous Close
€65.76
Day High
€68.73
Day Low
€66.04
52 Week High
01/23/15 - €68.73
52 Week Low
02/5/14 - €38.85
Market Cap
67.3B
Average Volume 10 Days
7.7K
EPS TTM
--
Shares Outstanding
984.3M
EX-Date
12/30/14
P/E TM
--
Dividend
€1.13
Dividend Yield
1.34%
Current Stock Chart for MEDTRONIC INC (MDT)

medtronic inc (MDT) Details

Medtronic, Inc. manufactures and sells device-based medical therapies worldwide. It operates through three segments: Cardiac and Vascular Group, Restorative Therapies Group, and Diabetes Group. The Cardiac and Vascular Group’s products include pacemakers; insertable cardiac monitors; implantable defibrillators; leads and delivery systems; ablation products; electrophysiology catheters; products for the treatment of atrial fibrillation; information systems for the management of patients with cardiac rhythm disease management devices; products to reduce surgical site infections; coronary and peripheral stents and related delivery systems; therapies for uncontrolled hypertension; endovascular stent graft systems; heart valve replacement technologies; cardiac tissue ablation systems; and open heart and coronary bypass grafting surgical products. The Restorative Therapies Group offers products for various areas of the spine; bone graft substitutes; biologic products; trauma, implantable neurostimulation therapies, and drug delivery systems for the treatment of chronic pain, movement disorders, obsessive-compulsive disorder, overactive bladder, urinary retention, fecal incontinence, and gastroparesis; products to treat conditions of the ear, nose, and throat; and systems that incorporate advanced energy surgical instruments. It also manufactures and sells image-guided surgery and intra-operative imaging systems. The Diabetes Group’s products include insulin pumps; continuous glucose monitoring systems; insulin pump consumables; and Web-based therapy management software solutions. The company serves hospitals, physicians, clinicians, and patients in approximately 140 countries. Medtronic, Inc. was founded in 1949 and is headquartered in Minneapolis, Minnesota.

49,247 Employees
Last Reported Date: 06/20/14
Founded in 1949

medtronic inc (MDT) Top Compensated Officers

Chairman and Chief Executive Officer
Total Annual Compensation: $1.5M
Chief Financial Officer, Principal Accounting...
Total Annual Compensation: $774.9K
Executive Vice President and Group President ...
Total Annual Compensation: $724.9K
Executive Vice President and Group President ...
Total Annual Compensation: $675.1K
Chief Human Resources Officer and Senior Vice...
Total Annual Compensation: $781.7K
Compensation as of Fiscal Year 2014.

medtronic inc (MDT) Key Developments

Medtronic Introduces Enhanced Therapy to Treat Debilitating Symptoms of Serious Stomach Disorder

Medtronic, Inc. announced it has received United States Food and Drug Administration (FDA) approval, under a humanitarian device exemption (HDE), for the Medtronic Enterra II System. The system is used to treat chronic, intractable (drug-refractory) nausea and vomiting associated with gastroparesis of diabetic or unknown origin when more conservative treatments fail or cannot be tolerated. Medtronic Enterra Therapy consists of a small medical device called a neurostimulator, which is implanted under the skin, usually in the lower abdominal region. Two insulated wires, called leads, are implanted in the stomach wall muscle and then connected to the neurostimulator, which delivers mild electrical pulses through the leads to stimulate the smooth muscles of the lower stomach. After the device is implanted, the doctor uses a handheld, external programmer to noninvasively adjust the neurostimulator and customize the stimulation to each patient's needs. Medtronic Enterra Therapy can be turned on and off at any time using the physician programmer. While Medtronic Enterra Therapy has been available to patients since 2000, the new Enterra II System improves the therapy by providing physicians with greater system flexibility and ease of use. The Enterra II System features improved programming software, improvements to the system's battery-life indicator, and a customized tool that simplifies implantation of the device for physicians.

Medtronic Launches MiniMed 640G System

Medtronic, Inc. announced the start of the global launch of the MiniMed(TM) 640G System, the next breakthrough toward an artificial pancreas. With the introduction of Medtronic's exclusive SmartGuard(TM) technology, MiniMed 640G is designed to help people with diabetes achieve better glucose control through advanced protection from hypoglycemia. The system is the first in the world to both automatically suspend insulin delivery when sensor glucose levels are predicted to approach a low limit and resume insulin delivery once sensor glucose levels recover. The system includes the Enhanced Enlite(TM) sensor, which continuously monitors glucose levels with accuracy and comfort1,2. It also incorporates a new insulin pump design to provide convenient diabetes management with a simple user interface, full-color screen, waterproofing3 and remote bolus. SmartGuard (or predictive low glucose management) technology, in the world, is designed to optimise the MiniMed 640G System's ability to better protect people with diabetes against lows throughout the day and night with multiple low-limit settings that can be tailored to individual needs.Convenient new features include a simpler menu, full-color, light-adjusting screen, customizable alerts and alarms, and waterproofing in up to 12 feet of water for 24 hours at a time. In addition, the MiniMed 640G System exclusively uses the Bayer CONTOUR(R) NEXT LINK 2.4 blood glucose meter to provide highly accurate blood glucose testing7, automatically transmit blood glucose results into the Bolus Wizard(TM) calculator to help ensure that patients do not have a manual entry error, and to calibrate the Enhanced Enlite sensor. It also allows patients to discreetly give a bolus of insulin remotely from the meter. The meter provides added convenience to help patients manage their diabetes effectively.

Federal Trade Commission Approves Final Order Preserving Future Competition in the Market for Drug-coated Balloon Catheters Used to Treat Peripheral Artery Disease

The Federal Trade Commission has approved a final order settling charges that Medtronic, Inc.'s $42.9 billion acquisition of Covidien plc would likely be anticompetitive. Under the order, first announced in November 2014, the companies agreed to sell Covidien's drug-coated balloon catheter business to a Colorado-based medical device company, The Spectranetics Corporation. According to the complaint, Medtronic and Covidien were developing products to compete with C.R. Bard, Inc., the only U.S. supplier of drug-coated balloon catheters used to treat peripheral artery disease.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
MDT:GR €68.37 EUR +2.61

MDT Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Abbott Laboratories $43.86 USD -0.63
Allergan Inc/United States $224.17 USD +1.38
Astellas Pharma Inc ¥1,784 JPY -33.00
Covidien PLC $108.07 USD +1.62
Stryker Corp $92.70 USD -0.67
View Industry Companies
 

Industry Analysis

MDT

Industry Average

Valuation MDT Industry Range
Price/Earnings 26.6x
Price/Sales 4.4x
Price/Book 3.9x
Price/Cash Flow 23.2x
TEV/Sales 2.8x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact MEDTRONIC INC, please visit www.medtronic.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.